Today's noteworthy upgrades include: ACE Limited (ACE) upgraded to Outperform at Bernstein on Chubb deal potential... Aixtron (AIXG) upgraded to Outperform from Neutral at Exane BNP Paribas... Anglo American (AAUKY) upgraded to Neutral from Underperform at Exane BNP Paribas... Antero Resources (AR) upgraded to Buy from Accumulate at KLR Group... Autoliv (ALV) upgraded to Outperform from Neutral at Credit Suisse... Barrick Gold (ABX) upgraded to Hold from Sell at Canaccord... California Water Service (CWT) upgraded to Buy from Neutral at Hilliard Lyons... Calpine (CPN) upgraded to Buy from Hold at Evercore ISI... CenturyLink (CTL) upgraded to Hold from Underperform at Jefferies... China Unicom (CHU) upgraded to Hold from Reduce at HSBC... Chubb (CB) upgraded to Outperform from Market Perform at Bernstein... Delphi (DLPH) upgraded to Buy from Outperform at CLSA... Diebold (DBD) upgraded to Outperform from Neutral at Wedbush... Discovery (DISCA) upgraded to Neutral from Sell at UBS... Eldorado Gold (EGO) upgraded to Buy at Canaccord... GoPro (GPRO) upgraded to Buy with $90 price target at Citi... Guidance Software (GUID) upgraded to Buy from Hold at Gabelli... H&E Equipment (HEES) upgraded to Buy from Neutral at UBS... Integra LifeSciences (IART) upgraded to Overweight from Neutral at JPMorgan... Lenovo (LNVGY) upgraded to Hold from Underperform at Jefferies... Methanex (MEOH) upgraded to Buy from Hold at TD Securities... Molina Healthcare (MOH) upgraded on strong results at Stifel... NCI, Inc. (NCIT) upgraded to Outperform from Market Perform at Cowen... Nationstar (NSM) upgraded to Market Perform from Underperform at FBR Capital... NetScout (NTCT) upgraded at Sterne Agee CRT... Pacira (PCRX) upgraded to Neutral from Underperform at BofA/Merrill... Premiere Global (PGI) upgraded to Strong Buy from Outperform at Raymond James... Regal Entertainment (RGC) upgraded to Outperform from Neutral at Wedbush... ResMed (RMD) upgraded to Overweight from Equal Weight at Morgan Stanley... RingCentral (RNG) upgraded to Strong Buy from Outperform at Raymond James... Robert Half (RHI) upgraded to Buy from Hold at Jefferies... SkyWest (SKYW) upgraded to Buy from Hold at Evercore ISI... Stratasys (SSYS) upgraded to Overweight from Neutral at Piper Jaffray... Under Armour (UA) upgraded to Buy from Hold at Argus... Western Union (WU) upgraded to Equal Weight from Underweight at Barclays... Yahoo Japan (YAHOY) upgraded to Buy from Hold at Jefferies... eHealth (EHTH) upgraded to Neutral from Underperform at BofA/Merrill.

Stifel raised the firm's price target on Eldorado Gold to C$19.50 from C$17.25 and keeps a Hold rating on the shares.

Still expects 2024 GAAP net income ($40M)-($20M) and adjusted EBITDA ($5M)-$20M.

California Water Service confirmed that its water systems will meet the new state maximum contaminant level of 10 parts per billion for chromium-6, which was adopted today by the State Water Resources Control Board. Cal Water developed and installed treatment for the contaminant in its impacted water systems in Dixon, Oak Hills (Salinas), Las Lomas (Salinas), and Willows when the same chromium-6 MCL, which was subsequently vacated for administrative reasons, was originally set in 2014. In fact, Cal Water's treatment system design was used as a model for other water utilities. After the MCL was vacated, Cal Water continued to treat those wells to protect customer health and safety. Cal Water plans to install treatment at a newer well that was brought online in Oak Hills, as well as at another well in Dixon that currently does not serve customers but could, if needed, within the two- to four-year compliance timeline. All other active wells above the MCL in these service areas are already being treated. "We take our responsibility to protect our customers' health and safety very seriously; that's why we continued to treat impacted water systems after the chromium-6 MCL was temporarily vacated," said Martin A. Kropelnicki, Cal Water Chairman & CEO. "We remain committed to meeting all state and federal standards set to protect public health and safety."

Shares of sleep apnea device makers ResMed (RMD) and Inspire Medical (INSP) are moving in opposite directions after Eli Lilly (LLY) announced topline results of the SURMOUNT-OSA Phase 3 clinical trials, showing tirzepatide injection significantly reduced the apnea-hypopnea index, or AHI, compared to placebo, achieving the primary endpoints of the studies. After initially moving... To see the rest of the story go to thefly.com. See Story Here

Shares of sleep apnea device makers ResMed (RMD) and Inspire Medical (INSP) are slipping in early trading after Eli Lilly (LLY) announced topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection significantly reduced the apnea-hypopnea index, or AHI, compared to placebo, achieving the primary endpoints of the studies. SURMOUNT-OSA Study 1 evaluated tirzepatide, which Lilly identifies as "the only approved GIP and GLP-1 treatment for chronic weight management, commercialized as Zepbound in the U.S. and Mounjaro in some global markets outside the U.S.," in adults with moderate-to-severe obstructive sleep apnea, or OSA, and obesity who were not on positive airway pressure, or PAP, therapy for 52 weeks. In Wednesday pre-market trading, ResMed shares are down about 3% to $180, while Inspire shares have slipped about 1% to $220.

Morgan Stanley upgraded Antero Resources to Overweight from Equal Weight with a price target of $36, up from $26. The analyst sees the company providing attractive leverage to rising gas prices and leading exposure to the growing liquified natural fairway in the Gulf Coast. Despite being an Appalachia producer, Antero has advantaged pipeline contracts that allow it to sell all of its production out of the basin, the analyst tells investors in a research note.